Want to see NRIX full AI Analyst Report?
NRIX Stock Chart & Stats
$23.38
$0.05(0.21%)
At close: 4:00 PM EDT
$23.38
$0.05(0.21%)
Day’s Range― - ―
52-Week Range$8.20 - $28.23
Previous Close$23.43
Volume1.28M
Average Volume (3M)1.94M
Market Cap
$2.88B
Enterprise Value$1.47B
Total Cash (Recent Filing)$443.53M
Total Debt (Recent Filing)$58.14M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Feb 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.45
Shares Outstanding103,781,685
10 Day Avg. Volume1,099,332
30 Day Avg. Volume1,935,677
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)2.72
Price to Sales (P/S)17.45
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue40.02
Enterprise Value/Gross Profit-24.18
Enterprise Value/Ebitda-4.60
Forecast
1Y Price Target
$34.25Price Target Upside46.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$56.80M
Bulls Say, Bears Say
Bulls Say
Roche Partnership Strengthens Funding And Development CapacityThe Roche alliance materially improves Nurix’s funding outlook and adds global development, manufacturing, and commercial capabilities. Cost sharing and potential milestone economics can extend runway while accelerating bexobrutideg’s development and market reach.
Bexobrutideg Shows Encouraging Clinical ActivityStrong response rates across difficult-to-treat and earlier-line CLL/SLL populations support the asset’s clinical differentiation. Favorable tolerability and CNS penetration could enable broader late-stage development and combination opportunities.
Low Leverage Provides Financial FlexibilityModest debt relative to equity and a sizable asset base reduce balance-sheet leverage risk compared with heavily indebted development-stage peers. This gives Nurix more flexibility to absorb volatility while partnerships and pipeline programs mature.
Bears Say
Revenue Contraction And Widening LossesNurix remains dependent on collaboration-related revenue rather than commercial product sales, and recent revenue contraction alongside deeper losses reduces earnings visibility. Persistent negative profitability raises the importance of successful clinical and partnering outcomes.
Persistent And Substantial Cash BurnHeavy operating and free-cash-flow deficits indicate that current activities consume substantial capital before products generate recurring sales. Even with partnership support, continued burn could create future dependence on milestones, licensing income, or additional financing.
No Commercial Product RevenueThe lack of marketed products leaves Nurix exposed to clinical, regulatory, and partner-execution risk, with no established recurring commercial revenue base. Long-term financial performance therefore depends heavily on advancing candidates and converting partnerships into milestones or royalties.
Nurix Therapeutics News
NRIX FAQ
What was Nurix Therapeutics, Inc.’s price range in the past 12 months?
Nurix Therapeutics, Inc. lowest stock price was $8.20 and its highest was $28.23 in the past 12 months.
What is Nurix Therapeutics, Inc.’s market cap?
Nurix Therapeutics, Inc.’s market cap is $2.88B.
When is Nurix Therapeutics, Inc.’s upcoming earnings report date?
Nurix Therapeutics, Inc.’s upcoming earnings report date is Feb 17, 2027 which is in 180 days.
How were Nurix Therapeutics, Inc.’s earnings last quarter?
Nurix Therapeutics, Inc. released its earnings results on Jul 09, 2026. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.723 by -$0.087.
Is Nurix Therapeutics, Inc. overvalued?
According to Wall Street analysts Nurix Therapeutics, Inc.’s price is currently Undervalued.
Does Nurix Therapeutics, Inc. pay dividends?
Nurix Therapeutics, Inc. does not currently pay dividends.
What is Nurix Therapeutics, Inc.’s EPS estimate?
Nurix Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nurix Therapeutics, Inc. have?
Nurix Therapeutics, Inc. has 103,781,685 shares outstanding.
What happened to Nurix Therapeutics, Inc.’s price movement after its last earnings report?
Nurix Therapeutics, Inc. reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.723. Following the earnings report the stock price went down -6.602%.
Which hedge fund is a major shareholder of Nurix Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nurix Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.25 (46.49% Upside)
$34.25 (46.49% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 67%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 658.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.9%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.47%
Trailing 12-Months
Company Description
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
NRIX Stock 12 Month Forecast
Average Price Target
$34.25
▲(46.49% Upside)
Technical Analysis
Ownership Overview
0.17% Insiders
17.91% Mutual Funds
59.24% Other Institutional Investors
5.68% Public Companies and
Individual Investors